NurExone Biologic Inc.
NRXBF
$0.40
$0.000.40%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 57.40% | -6.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.61% | -8.94% | |||
| Operating Income | -31.61% | 8.94% | |||
| Income Before Tax | -26.59% | 4.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.59% | 4.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.59% | 4.78% | |||
| EBIT | -31.61% | 8.94% | |||
| EBITDA | -29.75% | 7.61% | |||
| EPS Basic | -21.25% | 15.34% | |||
| Normalized Basic EPS | -21.00% | 15.25% | |||
| EPS Diluted | -21.25% | 15.34% | |||
| Normalized Diluted EPS | -21.00% | 15.25% | |||
| Average Basic Shares Outstanding | 4.28% | 12.50% | |||
| Average Diluted Shares Outstanding | 4.28% | 12.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||